Printer Friendly

Acceleron announces updated results from luspatercept Phase 2 trials at EHA.

Acceleron (XLRN) announced updated results from the ongoing Phase 2 trials of luspatercept in patients with beta-thalassemia during an oral presentation at the 23rd Congress of the European Hematology Association, or EHA. Luspatercept is being developed as part of a global collaboration between Acceleron and Celgene (CELG). Beta-thalassemia is caused by a genetic defect in the production of hemoglobin, a protein that carries oxygen to red blood cells throughout the body. Patients suffer from severe, chronic anemia and often experience fatigue, organ enlargement, and bone complications. Patients require lifelong therapy that includes frequent red blood cell transfusions and corresponding treatment for the iron overload that results. A total of 31 non-transfusion-dependent patients have been treated with luspatercept in the trials. A total of 32 transfusion-dependent patients have been treated with luspatercept in the trials.

COPYRIGHT 2018 The Fly
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2018 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:The Fly
Date:Jun 15, 2018
Previous Article:GI Partners enters pact with Amag Pharmaceuticals to acquire Cord Blood Registry.
Next Article:Buy-side expectations for FedEx 'not elevated,' says Credit Suisse.

Terms of use | Privacy policy | Copyright © 2019 Farlex, Inc. | Feedback | For webmasters